Yang Patrick Y 4

What Happened

Patrick Y. Yang, a director of Sana Biotechnology, was granted a derivative award covering 90,000 shares on June 4, 2026. The Form 4 records the acquisition price as $0.00 (derivative award) and a total reported value of $0. The award is an option that, per the filing footnote, vests and becomes exercisable 100% on the earlier of June 4, 2027 or immediately prior to Sana’s 2027 annual meeting, provided Yang remains in continuous service through that date. This was a compensation grant (award), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-05) — filing appears timely.
• Transaction type: A = Grant / Award (derivative)
• Shares/options granted: 90,000 shares (derivative)
• Price reported: $0.00 (award); total reported value $0
• Vesting/exercise: 100% vests/becomes exercisable on earlier of June 4, 2027 or immediately prior to 2027 annual meeting, subject to continuous service (Footnote F1).
• Shares owned after the transaction: not specified in the supplied filing summary.
• Exhibit: Power of Attorney listed (Ex. 24).

Context

• This grant is a compensation award (option) to a director; it does not represent an open-market purchase or sale. The award becomes exercisable in one year if the director remains in service.
• Exercise has not occurred and no exercise price or subsequent sale is reported here; the filing just documents the grant and vesting/exercise schedule.